Scinai Immunotherapeutics to Acquire Rare Disease Firm Pincell

TL;DR

Scinai inks deal to buy Pincell, gaining access to rare disease tech for skin issues.

AI Summary

On March 27, 2025, Scinai Immunotherapeutics Ltd. announced it has signed an option agreement to acquire Pincell, a rare disease company. This acquisition includes Pincell's novel antibody designed to treat severe dermatological conditions.

Why It Matters

This potential acquisition could expand Scinai's pipeline into rare diseases and novel antibody treatments for severe skin conditions.

Risk Assessment

Risk Level: medium — The filing is an announcement of an option agreement, not a completed acquisition, and the success of the acquired technology is not yet proven.

Key Players & Entities

• Scinai Immunotherapeutics Ltd. (company) — Filing company
• Pincell (company) — Company to be acquired
• March 27, 2025 (date) — Date of press release

FAQ

From the Filing

0001013762-25-003143.txt : 20250327 0001013762-25-003143.hdr.sgml : 20250327 20250327121639 ACCESSION NUMBER: 0001013762-25-003143 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20250327 FILED AS OF DATE: 20250327 DATE AS OF CHANGE: 20250327 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Scinai Immunotherapeutics Ltd. CENTRAL INDEX KEY: 0001611747 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37353 FILM NUMBER: 25777823 BUSINESS ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 BUSINESS PHONE: 972-8-9302529 MAIL ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: BiondVax Pharmaceuticals Ltd. DATE OF NAME CHANGE: 20140624 6-K 1 ea0235923-6k_scinai.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of March 2025 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Explanatory Note On March 27, 2025, Scinai Immunotherapeutics Ltd. issued a press release announcing the signing of an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions. A copy of the press release is furnished herewith as Exhibit 99.1. This Report on Form 6-K is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-271293 and File No. 333-239344 ) and Form F-3 (File No. 333-274078 and File No. 333-276767 ), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. 1 Exhibit Index Exhibit No. Description 99.1 Press release dated March 27, 2025. 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Scinai Immunotherapeutics Ltd. Date: March 27, 2025 By: /s/ Amir Reichman Amir Reichman Chief Executive Officer 3 EX-99.1 2 ea023592301ex99-1_scinai.htm PRESS RELEASE DATED MARCH 27, 2025 Exhibit 99.1 Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions Scinai files an application for Euro 12 million grant to fund next stage of development ● Pincell’s monoclonal antibody, PC111, is in development for treating Pemphigus, Steven Johnson’s Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) ● PC111 has already received an Orphan Drug Designation in Pemphigus by the European Medicine’s Agency ● An application will be filed with the FDA for Orphan Drug and Breakthrough Designation in Pemphigus, as well as in SJS/TEN ● Scinai sees potential for accelerated approval given the severity of these diseases, PC111’s innovative, non-immunosuppressive mode of action and the lack of effective alternative treatments JERUSALEM, ISRAEL – March 27, 2025 - Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and in providing CDMO services through its Scinai Bioservi